209 related articles for article (PubMed ID: 11569989)
1. Lipodystrophy--nukes vs. protease inhibitors.
TreatmentUpdate; 2001 Jul; 13(3):5-6. PubMed ID: 11569989
[No Abstract] [Full Text] [Related]
2. [AIDS triple therapy. The gap between viral load and side effects].
Gürtler L
Fortschr Med; 1998 Sep; 116(27):4-5. PubMed ID: 9816747
[No Abstract] [Full Text] [Related]
3. Focus on fat.
TreatmentUpdate; 2002 Nov; 14(8):4. PubMed ID: 12501822
[No Abstract] [Full Text] [Related]
4. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
[TBL] [Abstract][Full Text] [Related]
5. Standard treatments for HIV, Spring 1997.
Smith D
AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
Brinkman K; Smeitink JA; Romijn JA; Reiss P
Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
[TBL] [Abstract][Full Text] [Related]
7. The new body of AIDS: Crixivan bellies, legs, and humps.
McCabe L
Newsline People AIDS Coalit N Y; 1998 Sep; ():37-9. PubMed ID: 11367490
[TBL] [Abstract][Full Text] [Related]
8. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980
[No Abstract] [Full Text] [Related]
9. [Switch strategy: replacing the protease inhibitor. Quality of life improves].
MMW Fortschr Med; 2000; 142(3 Suppl):37. PubMed ID: 11012292
[No Abstract] [Full Text] [Related]
10. Pathogenesis of HIV-associated lipodystrophy.
Wanke C
AIDS Clin Care; 2000 Dec; 12(12):100. PubMed ID: 12211161
[No Abstract] [Full Text] [Related]
11. No nukes please.
TreatmentUpdate; 2002 Nov; 14(8):6. PubMed ID: 12501825
[No Abstract] [Full Text] [Related]
12. New anti-HIV drug interactions, toxicities, and dosing options.
Bartnof HS
BETA; 1999; 12(4):60-3, 66. PubMed ID: 11367260
[TBL] [Abstract][Full Text] [Related]
13. Anti-HIV agents. Leading to lipodystrophy.
TreatmentUpdate; 2007 Feb; 19(2):3-4. PubMed ID: 17447312
[No Abstract] [Full Text] [Related]
14. Choosing the right initial antiretroviral regimens.
Norton M
GMHC Treat Issues; 1999 Feb; 13(2):7-10. PubMed ID: 11366117
[TBL] [Abstract][Full Text] [Related]
15. The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen.
Leitz G; Robinson P
AIDS; 2000 Mar; 14(4):468-9. PubMed ID: 10770555
[No Abstract] [Full Text] [Related]
16. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
Nolan D; John M; Mallal S
Antivir Ther; 2001 Sep; 6(3):145-60. PubMed ID: 11808750
[TBL] [Abstract][Full Text] [Related]
17. Cohort studies: what do they tell us?
Chêne G
J HIV Ther; 2001 May; 6(2):28-31. PubMed ID: 11501200
[No Abstract] [Full Text] [Related]
18. Drug interactions, toxicities, dosages: trials and tribulations and cocktails.
Crit Path AIDS Proj; 1998; (No 33):9-17. PubMed ID: 11366377
[TBL] [Abstract][Full Text] [Related]
19. On the trail of fugitive fat: the chase turns to NRTIs.
Mascolini M
J Int Assoc Physicians AIDS Care; 1999 Oct; 5(10):24-43. PubMed ID: 11366871
[TBL] [Abstract][Full Text] [Related]
20. "What you lookin' at?".
Gormley F
GMHC Treat Issues; 2001 May; 15(5):5-6. PubMed ID: 11548302
[No Abstract] [Full Text] [Related]
[Next] [New Search]
